

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31st DECEMBER, 2022

(₹ in Millions, unless otherwise stated)

Sr. No.	Particulars	Quarter ended			Nine Months Ended		Year ended
		31 Dec'22	30 Sep'22	31 Dec'21	31 Dec'22	31 Dec'21	31 Mar'22
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
I	Income						
	Revenue from Operations	5,407.31	5,092.99	5,224.99	15,399.00	16,091.57	21,232.14
	Other Income	66.08	100.20	35.34	261.21	96.09	147.04
	Total Income	5,473.39	5,193.19	5,260.33	15,660.21	16,187.66	21,379.18
II	Expenses						
	Cost of Materials Consumed	2,693.25	2,682.07	2,386.36	7,987.82	7,402.91	10,015.63
	Changes in Inventories of Finished Goods and Work-in-Progress	(44.92)	(282.30)	185.36	(650.72)	474.71	413.24
	Employee Benefits Expense	485.41	473.69	441.31	1,363.66	1,296.40	1,687.23
	Finance Costs	1.60	1.33	0.61	4.28	278.37	279.62
	Depreciation and Amortisation Expense	107.63	99.35	97.39	305.77	283.23	378.77
	Other Expenses	819.01	783.14	751.32	2,339.61	2,179.06	2,955.44
	Total Expenses	4,061.98	3,757.28	3,862.35	11,350.42	11,914.68	15,729.93
III	Profit Before Tax (I-II)	1,411.41	1,435.91	1,397.98	4,309.79	4,272.98	5,649.25
IV	Tax Expenses						
	Current Tax	331.78	338.93	319.36	1,033.00	1,007.22	1,376.27
	Deferred Tax	29.70	28.20	41.49	70.75	67.49	85.74
	Total Tax Expenses	361.48	367.13	360.85	1,103.75	1,074.71	1,462.01
V	Profit for the Period / Year (III-IV)	1,049.93	1,068.78	1,037.13	3,206.04	3,198.27	4,187.24
VI	Other Comprehensive Income (OCI) Items that will not be reclassified to profit or loss						
	(a) Re-measurement of the post-employment benefit obligation	(2.96)	(6.31)	0.94	(8.88)	(2.63)	1.30
	(b) Income tax relating to the above	0.74	1.59	(0.24)	2.23	0.66	(0.33)
	Total Other Comprehensive Income / (Loss)	(2.22)	(4.72)	0.70	(6.65)	(1.97)	0.97
VII	Total Comprehensive Income for the Period / Year (V+VI)	1,047.71	1,064.06	1,037.83	3,199.39	3,196.30	4,188.21
VIII	Earnings per equity share (Face Value of ₹ 2/- each) (Not Annualised except for the year ended 31st March)						
	(a) Basic (in ₹)	8.57	8.72	8.65	26.16	27.60	35.63
	(b) Diluted (in ₹)	8.57	8.72	8.65	26.16	27.60	35.63
IX	Paid up Equity Share Capital, Equity Shares of ₹ 2/- each	245.05	245.05	245.05	245.05	245.05	245.05
X	Other Equity excluding Revaluation Reserve						20,298.07

See accompanying notes to the Financial Results



Glenmark Life Sciences Limited

Corporate Office: 4th Floor, OIA House, 470, Cardinal Gracious Road, Andheri (E), Mumbai, 400 099, India. Registered

Office: Plot No. 170-172, Chandramouli Industrial Estate, Mohol Bazarpet, Solapur - 413 213, India.

T: 91 22 68297979 CIN: L74900PN2011PLC139963 E: complianceofficer@glenmarklifesciences.com

W: www.glenmarklifesciences.com

Notes:

1. The Financial Results have been prepared in accordance with Indian Accounting Standards ("Ind AS") prescribed under section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended).
2. The above Financial Results were reviewed by Audit Committee and thereafter approved and taken on record by the Board of Directors at their meeting held on January 27, 2023. These results have been subjected to limited review by statutory auditor who have issued an unmodified conclusion on the said results.
3. Details of Utilisation of IPO Proceeds is as under:

(₹ in millions)

Particulars	Estimated net proceeds as per Prospectus	Revised Net Proceeds	Utilised up to 31 Dec'22	Unutilised as on 31 Dec'22
Payment of outstanding purchase consideration to the Promoter for the spin-off of the API business from the Promoter into our Company pursuant to the Business Purchase Agreement dated October 9, 2018	8,000.00	8,000.00	8,000.00	-
Funding the capital expenditure requirements	1,527.64	1,527.64	1,083.12	444.52
General corporate purposes	576.75	494.40	494.40	-
Total	10,104.39	10,022.04	9,577.52	444.52

Unutilised amount as at December 31, 2022 were held in monitoring agency account and in deposits with scheduled commercial bank.

4. The Company has identified only one segment i.e. Active Pharmaceutical Ingredient (API) as reporting segment based on the information reviewed by Chief Operating Decision Maker (CODM).
5. As at December 31, 2022, pursuant to Employee Stock Option Plan 2021, 8,88,885 options were outstanding, which upon exercise are convertible into equivalent number of equity share.

For Glenmark Life Sciences Limited



Yasir Rawjee
Managing Director & CEO

Mumbai, January 27, 2023



Glenmark Life Sciences Limited

Corporate Office: 4th Floor, OIA House, 470, Cardinal Gracious Road, Andheri (E), Mumbai, 400 099, India. Registered

Office: Plot No. 170-172, Chandramouli Industrial Estate, Mohol Bazarpeth, Solapur - 413 213, India.

T: 91 22 68297979 CIN: L74900PN2011PLC139963 E: complianceofficer@glenmarklifesciences.com

W: www.glenmarklifesciences.com